Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM34TXO)

• Drug Name: Dapagliflozin Propanediol; Saxagliptin Hydrochloride Drug Info
• Synonyms: Saxagliptin Hydrochloride; Qtern

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Approved	[1]

• Cross-matching ID: TTD Drug ID: DM34TXO

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium/glucose cotransporter 2 (SGLT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dapagliflozin	DM28UJG	Non-insulin dependent diabetes	5A11	Approved	[3]
Empagliflozin	DMRF9YK	Type-1 diabetes	5A10	Approved	[3]
Canagliflozin	DMFRM1I	Non-insulin dependent diabetes	5A11	Approved	[4]
PF-04971729	DM79VXT	Type-2 diabetes	5A11	Approved	[5]
Sotagliflozin	DMMLXA9	Heart failure	BD10-BD13	Approved	[6]
ASP1941	DMGQ1TV	Liver disease	DB90-BD99	Phase 3	[7]
Remogliflozin etabonate	DMW4YK1	Type-1/2 diabetes	5A10-5A11	Phase 2	[8]
LIK-066	DM32NWD	Heart failure	BD10-BD13	Phase 2	[9]
AVE-2268	DMA42BV	Diabetic complication	5A2Y	Phase 2	[10]
YM-543	DMRZBPI	Type-2 diabetes	5A11	Phase 2	[11]

Drug(s) Targeting Dipeptidyl peptidase 4 (DPP-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Saxagliptin	DMGXENV	Type-2 diabetes	5A11	Approved	[12]
Sitagliptin	DMGDKXN	Cystic fibrosis	CA25	Approved	[13]
Alogliptin	DM8WI3R	Type-2 diabetes	5A11	Approved	[14]
Linagliptin	DMWFJTR	Non-insulin dependent diabetes	5A11	Approved	[15]
Vildagliptin	DMYN59P	Type-2 diabetes	5A11	Approved	[16]
Anagliptin	DMJXIC9	Type-2 diabetes	5A11	Approved	[17]
SaxaDapa FDC	DMAPRWV	Diabetic complication	5A2Y	Phase 3	[18]
LC-150444	DM09RKB	Type-2 diabetes	5A11	Phase 3	[19]
Dutogliptin	DMM5VTA	Type-2 diabetes	5A11	Phase 3	[20]
MK-3102	DM3PSUF	Type-2 diabetes	5A11	Phase 3	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dipeptidyl peptidase 4 (DPP-4)	TTDIGC1	DPP4_HUMAN	Modulator	[2]
Sodium/glucose cotransporter 2 (SGLT2)	TTLWPVF	SC5A2_HUMAN	Modulator	[2]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [5] Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.Diabetes Obes Metab.2015 Jun;17(6):591-8.
• [6] LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
• [7] Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.World J Diabetes.2015 Feb 15;6(1):136-44.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80.
• [11] Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor. Endocr Res. 2013 Aug;38(3):168-183.
• [12] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [13] Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
• [14] Clinical pipeline report, company report or official report of Takeda (2009).
• [15] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [16] Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
• [17] Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
• [18] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
• [19] Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
• [20] Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.
• [21] Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12.